BioHarvest Sciences Inc. Common Stock Q3 2026 Earnings Call Summary
BioHarvest (BHST) Q3 2026 Earnings Call Transcript
BioHarvest Sciences posts US$7.9M Q3 revenue as fragrance supply deal sets up 2027 growth
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates
BioHarvest Reports Third Quarter 2026 Financial Results and Provides Business Update
Conference call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $37.000M-$40.000M to $32.000M-$33.500M vs $37.461M Est
BioHarvest Sciences Inc. (BHST) Q3 2026 Earnings Call Transcript
BioHarvest Sciences Q3 2026 Earnings Call Transcript
BioHarvest Sciences Inc. - Common Stock Q3 EPS $(0.15) Misses $(0.14) Estimate, Sales $7.867M Miss $9.371M Estimate
BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026
BioHarvest takes second plant-cell asset to commercial readiness
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
BioHarvest Sciences' Proprietary Olive Cell Composition Attains Commercial Readiness, Now Available For Licensing And Commercialization
Tate & Lyle (LSE:TATE) Reaches Next Generation Sweetener Milestone
BioHarvest says its platform can produce target sweetener in Tate & Lyle program
Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme
BioHarvest Sciences launches buyback of up to 5% of shares
BioHarvest Sciences Announces Share Repurchase Program
BioHarvest Sciences Board Authorizes Normal Course Issuer Bid To Repurchase Up To 5% Of Outstanding Common Shares
BioHarvest Sciences launches single-dose VINIA Daily Chews
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.